🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 00847G804 (prev. 00847G705 )
- Market Cap
- Mid Cap
- IPO
- 2/9/2000 · $18.00/share
- Previous Name
- Antigenics, Inc.
Business: Agenus is an immunology company developing a series of Checkpoint Modulators for the treatment of patients with cancer, infectious diseases, and other immune disorders, heat shock protein (HSP)-based vaccines, and immune adjuvants. The company’s proprietary discovery engine Retrocyte Display is used to generate fully human and humanized therapeutic antibody drug candidates.
Notes: April 05, 2024 -- Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced its stockholders have approved a one-for-twenty reverse stock split of its issued and outstanding common stock, which will go into effect at 12:01 a.m., Eastern Time on April 12, 2024. The reverse stock split is intended to give Agenus greater flexibility in its future financing needs and to increase the per share trading price of Agenus’ common stock to satisfy the minimum price requirement for continued listing on the Nasdaq Capital Markets and to qualify for inclusion in the Russell Indices. Agenus expects that upon the opening of trading on April 12, 2024, its common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the current trading symbol “AGEN” and the new CUSIP number 00847G804.
Company Contact
- CEO
- Garo H. Armen
- CFO
- Christine Klaskin
- Headquarters
- 3 Forbes Road, Lexington, MA 02421
- Phone
- 781-674-4400
- Investor Relations
- Jennifer Buell · 781-674-4420 · Jennifer.Buell@agenusbio.com